EU approves FREHEMGO (denecimig) for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing – Novo
Novo announced that the European Commission has granted marketing authorisation for FREHEMGO (denecimig) as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and… read more.


